patient | Page 53 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

patient

  1. Home

VEXAS Syndrome

In this webinar, Dr. David Beck, MD, PhD and Anna Cantor, MA, MS, CGC, discuss VEXAS syndrome which is a newly discovered auto-inflammatory condition affecting older adults.  VEXAS syndrome often overlaps with

David Beck, MD, PhD

Beck, David
Assistant Professor, Department of Medicine
NYU Grossman School of Medicine

My research focuses on identifying the genetic causes of human diseases as a means to both better diagnosis and treat patients and understand basic biologic principles. We are interested in studying autoimmune and auto-inflammatory diseases to elucidate the mechanism underlying these diseases and improve patient care. We use a combination of genetic, and biochemical approaches in patient derived and animal models to better understand these diseases. Our aim is to directly connect human diseases with basic innate immune biology using genetics.

Online Profile: 
David Beck, MD, PhD

Suresh Balasubramanian

Balasubramanian, Suresh
Physician, Oncology - Hematology, Oncology - Medical
Karmanos Cancer Institute

Dr. Balasubramanian completed his medical training at Madras Medical College in India. His interest in treating malignant hematology patients started in his advanced training in Singapore in the Department of Hematology and Bone Marrow Transplant. He was intrigued by the advancement of cancer genetics and its application in the development of novel therapeutics.

Online Profile: 
Suresh Balasubramanian, M.D.

Catherine J. Lee, MD

Lee, Catherine
Associate Professor of Medicine
Fred Hutchinson Cancer Research Center

Dr. Catherine Lee's clinical expertise is in Blood and Marrow Transplantation (BMT) & Cellular Therapy. She specializes in autologous and allogeneic hematopoietic cell transplants for the treatment of malignant and benign hematologic diseases in adult patients. She also directs the clinical cellular therapy program and provides both standard-of-care cellular therapy treatments and those being tested in clinical trials.

Online Profile: 
Catherine J. Lee, MD

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

BOSTON, May 25, 2022  – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated